vadimezan has been researched along with combretastatin in 6 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (combretastatin) | Trials (combretastatin) | Recent Studies (post-2010) (combretastatin) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 223 | 1 | 127 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bentzen, S; Galbraith, SM; Lodge, MA; Padhani, AR; Rustin, GJ; Stirling, JJ; Taylor, NJ | 1 |
| Lee, AE; McKeage, MJ; Pruijn, FB; Shalal-Zwain, S; Siim, BG; Wilson, WR | 1 |
| Baguley, BC; Kanthou, C; Tozer, GM | 1 |
| Cai, YC; Xian, LJ; Zou, Y | 1 |
| Lenihan, DJ; Subbiah, IM; Tsimberidou, AM | 1 |
| Gevertz, JL | 1 |
2 review(s) available for vadimezan and combretastatin
| Article | Year |
|---|---|
Disrupting tumour blood vessels.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Capillary Permeability; Clinical Trials as Topic; Endothelial Cells; Humans; Neoplasms; Neovascularization, Pathologic; Stilbenes; Xanthones | 2005 |
[Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Diphosphates; Endothelial Cells; Humans; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Organophosphorus Compounds; Serine; Stilbenes; Tubulin Modulators; Xanthones | 2010 |
4 other study(ies) available for vadimezan and combretastatin
| Article | Year |
|---|---|
Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis.
Topics: Antineoplastic Agents; Bibenzyls; Contrast Media; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Muscle, Skeletal; Neoplasms; Reproducibility of Results; Stilbenes; Xanthenes; Xanthones | 2002 |
Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Carboplatin; Dose-Response Relationship, Drug; Drug Synergism; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Paclitaxel; Stilbenes; Time Factors; Xanthenes; Xanthones | 2003 |
Cardiovascular toxicity profiles of vascular-disrupting agents.
Topics: Angiogenesis Inhibitors; Bibenzyls; Cardiovascular System; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Quinazolines; Serine; Xanthones | 2011 |
Microenvironment-Mediated Modeling of Tumor Response to Vascular-Targeting Drugs.
Topics: Angiogenesis Inhibitors; Bevacizumab; Bibenzyls; Computer Simulation; Cytotoxins; Drug Combinations; Drug Dosage Calculations; Endothelial Cells; Everolimus; Humans; Models, Statistical; Neoplasms; Neovascularization, Pathologic; Tumor Microenvironment; Xanthones | 2016 |